BUZZ-Salarius jumps after completing merger with Decoy Therapeutics

Reuters11-13
BUZZ-Salarius jumps after completing merger with Decoy <a href="https://laohu8.com/S/LENZ">Therapeutics</a>

** Shares of drug developer Salarius Pharmaceuticals SLRX.O rise 17.3% to $1.22 in early trading

** Co and Decoy Therapeutics complete their merger, combining resources to accelerate development of peptide-based drugs for serious diseases - SLRX

** The merged co is renamed Decoy Therapeutics and focuses on advancing Decoy's pipeline, which includes treatments for respiratory infections and gastrointestinal cancers, co says

** SLRX says Frederick "Rick" Pierce, Decoy's co-founder, serves as chief executive officer

** Decoy's technology uses artificial intelligence and rapid manufacturing techniques to design and produce drug candidates quickly - SLRX

** Decoy secures funding from institutional investors and programs run by Massachusetts Life Sciences, Google, NVIDIA, and Johnson & Johnson

** Including session's move, stock down ~94% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment